Immunosuppressive agents in dermatology. An update

Area of Science:

• Dermatology
• Immunosuppressive Therapy

Background:

• Azathioprine, cyclophosphamide, methotrexate, and cyclosporine are key immunosuppressants in dermatology.
• Azathioprine is favored for chronic conditions due to its safety profile, with genetic polymorphism awareness enhancing its use.
• Cyclophosphamide offers rapid immunosuppression for severe diseases but carries significant toxicity.

Purpose of the Study:

• To review the clinical applications, efficacy, and safety profiles of commonly used immunosuppressive agents in dermatology.
• To highlight the expanding roles and specific considerations for azathioprine, cyclophosphamide, methotrexate, and cyclosporine.

Main Methods:

• Review of current literature on immunosuppressive agents used in dermatologic disorders.
• Analysis of disease-specific efficacy, side-effect profiles, and dosage considerations.

Main Results:

• Azathioprine: good safety, useful for chronic eczematous dermatitides and bullous disorders; genetic polymorphism impacts efficacy/safety.
• Cyclophosphamide: rapid onset for severe cutaneous disease, but significant short/long-term toxicity.
• Methotrexate: anti-inflammatory, broadening role in dermatoses despite hepatotoxicity.
• Cyclosporine: potent T-cell inhibition, used short-term for refractory psoriasis/atopic dermatitis due to renal toxicity.

Conclusions:

• Judicious use of these immunosuppressants requires familiarity with their disease-specific efficacy and side-effect profiles.
• Optimizing immunosuppressive therapy in dermatology involves understanding individual drug characteristics and patient factors.
• Ongoing research and clinical experience are expanding the therapeutic roles of these agents in managing complex dermatologic conditions.